论文部分内容阅读
目的比较孟鲁司特钠联合吸入丙酸氟替卡松与单用丙酸氟替卡松治疗支气管哮喘的疗效。方法将60例支气管哮喘患者随机分为观察组和对照组,每组各30例。二组均予平喘、止咳、化痰、吸氧等对症支持治疗,对照组吸入丙酸氟替卡松250μg,2次/d;观察组在对照组基础上再口服孟鲁司特钠10mg,每晚1次;观察治疗前及治疗3个月后第一秒用力呼气量(FEV1)、用力肺活量(FVC)及自测呼气峰值流速(PEF),并对哮喘临床症状积分及总体疗效进行评价。结果二组在治疗期间均未出现严重不良反应,观察组和对照组总有效率分别为93.3%、73.3%,差异有统计学意义(P<0.05),且观察组在临床控制率上显著高于对照组,差异有统计学意义(P<0.05)。二组治疗3个月后临床症状积分、FEV1、PEF、FVC均有显著改善,且观察组优于对照组,差异均有统计学意义(P<0.05)。结论口服孟鲁司特联合吸入丙酸氟替卡松治疗支气管哮喘疗效肯定,能有效改善患者的支气管症状和肺功能,提高患者生活质量。
Objective To compare the efficacy of montelukast sodium inhalation fluticasone propionate and fluticasone propionate alone in the treatment of bronchial asthma. Methods Sixty patients with bronchial asthma were randomly divided into observation group and control group, with 30 cases in each group. The patients in the two groups were treated with symptomatic relief of asthma, cough, phlegm, oxygen and other symptomatic supportive therapy. The control group was given fluticasone propionate 250 μg twice daily for 2 days. The observation group was given oral montelukast sodium 10 mg 1, and the first second forced expiratory volume (FEV1), forced vital capacity (FVC) and peak expiratory flow (PEF) were measured before treatment and 3 months after treatment, and the clinical symptom scores and overall efficacy of asthma were evaluated . Results The two groups showed no serious adverse reactions during the treatment. The total effective rates in the observation group and the control group were 93.3% and 73.3%, respectively, with significant difference (P <0.05), and the clinical control rate in the observation group was significantly higher In the control group, the difference was statistically significant (P <0.05). The scores of clinical symptoms, FEV1, PEF and FVC in the two groups after 3 months of treatment were significantly improved, and the observation group was superior to the control group, the difference was statistically significant (P <0.05). Conclusion Oral montelukast combined with fluticasone propionate treatment of bronchial asthma positive effect, can effectively improve the patient’s bronchial symptoms and lung function, improve patient quality of life.